Last reviewed · How we verify
radioprotection
radioprotection is a Small molecule drug developed by Radiation Therapy Oncology Group. It is currently in Phase 1 development.
Low-dose radiation therapy has been studied as a potential treatment for symptomatic facet joint arthritis, with one clinical trial evaluating its effectiveness in reducing pain levels. Intra-articular steroid injections and BIO 300 Oral Suspension have also been investigated in clinical trials for various conditions, including lower back pain and osteoarthritis.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | radioprotection |
|---|---|
| Sponsor | Radiation Therapy Oncology Group |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Clinical Utility of Radiation Exposure Reduction: Multi-site Rampart Guardian Peripheral Trial (NA)
- ATTENUATE (rAdpad proTecTion drapE iN redUcing rAdiaTion Exposure) Trial (NA)
- The Radiation ProtEction for Dose RedUction in the Cardiac CathEter Lab Study: The REDUCE Trial (NA)
- Phase 1 BIO 300 Oral Suspension (PHASE1)
- PMT-Based Radiation Safety Training for Nurses: Randomized Controlled Trial. (NA)
- Method for bAdge-dosi Monitoring of X-ray Exposure Values in Operating Theatre Surgery
- Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau (PHASE1)
- Zero-cost Radiation Protection Method to Reduce Radiation Exposure of Interventional Cardiologists During Transradial Percutaneous Coronary Procedures (FREEPADRAD Trial) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- radioprotection CI brief — competitive landscape report
- radioprotection updates RSS · CI watch RSS
- Radiation Therapy Oncology Group portfolio CI
Frequently asked questions about radioprotection
What is radioprotection?
Who makes radioprotection?
What development phase is radioprotection in?
Related
- Manufacturer: Radiation Therapy Oncology Group — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing